Skip to main content
Equibles
STIM $2.30 -1.71%
STIM logo
STIM · Neuronetics, Inc.
Track STIM — free

Use STIM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research STIM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.30 -0.04 (-1.71%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Therefore, substantial doubt exists about the Company's ability to continue as a going concern. Actions within the Company's control to meet its minimum revenue covenant include improvements to its revenue cycle management, introducing new treatment options at its clinic locations and pursuing new strategies within its NeuroStar business to accelerate sales growth and optimize its product mix. The Company's ability to meet its liquidity needs, including meeting future revenue and liquidity covenants, is dependent on growth in existing and acquired product and service lines and the realization of synergies related to its acquisition of Greenbrook. However, at this time, these actions do not fully mitigate the risk related to compliance with the revenue covenant for the March 31, 2027 period. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.”
View the 10-Q filed Aug 11, 2026
Market Cap
$208.78M
Shares
76.20M
Volume · Oct 1 695.37K Avg daily vol (3M) 2.08M
All earnings calls

Earnings call · FY2026 Q2

Neuronetics, Inc. (STIM) Q2 2026 Earnings Call

Concluded Aug 11, 2026
Aug 11, 2026 0 turns
Period
FY2026 Q2
Runtime
—
Sources
3 artifacts
Slides 26 8-K 10-Q

Executive readout · one minute

Call research workspace

Read the call alongside every captured source. slides, 8-K earnings release, 10-Q stay in one workspace.

Greenbrook clinic operational performance 32 Neurostar commercial model evolution 17 Path to profitability and cash generation 15 Revenue mix and gross margin drivers 15 Full-year guidance update 11 Cost discipline and OPEX reduction 10

Management tone

Positive

Net tone +45 · low hedging

Grounding quotes
  • “we grew revenue, improved our margins, reduced our cash burn, and strengthened our balance sheet, all while continuing to invest in the growth of the business”
  • “We also began using AI in the insurance authorization process, which has helped us reduce operating costs”
  • “Net loss for the quarter was $3.4 million, or $0.05 per share, compared to a net loss of $10.1 million, or $0.15 per share in the prior year”
  • “our session revenue was down double digits and our capital sales were up double digits”

Forward guidance

6 guided metrics

Management's latest ranges and targets are included below.

Research coverage

3 live sources

Open each available source without leaving this research workspace.

Revenue $41.57M +9.1% YoY
Diluted EPS -$0.05
Gross margin 51.1% +4.5 pp YoY
Net income -$3.44M

Research materials

Open the source you need; every reader stays inside this workspace.

Presentation 26 slides 8-K earnings release Filed Aug 11, 2026 10-Q report Filed Aug 11, 2026 Company webcastOpen the original investor-relations page

Forward guidance

From the 8-K filed Aug 11, 2026.

Metric Guided
Total revenue Initiated
full year 2026
 $160M – $164M
Gross margin Initiated
full year 2026
 48% – 50%
Operating expenses Initiated
full year 2026
 $95M – $100M
Operating expenses, less SBC Initiated
full year 2026
 $91M – $96M
Operating Expenses Initiated
FY 2026
 $91M – $96M
Cash Flow from Operations and Investing Initiated
FY 2026
 $-14.5M – $-10.5M

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Greenbrook Segment$26.89M +16.8% YoY
Neurostar Segment$14.68M -2.7% YoY
Full-screen source Call document

STIM transcript alerts

Neuronetics, Inc.

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →